Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Baxter
Costa Rica - Cartago
CEFEPIME HYDROCHLORIDE (cefepime) by Baxter is 12. Approved for the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa and 15 more indications. First approved in 2016.
Drug data last refreshed 20h ago
12.1 Mechanism of Action Cefepime is a cephalosporin antibacterial drug [ See ]. 12.2 Pharmacodynamics Similar to other beta-lactam antimicrobial agents, the time that the unbound plasma concentration of cefepime exceeds the MIC of the infecting organism has been shown to best correlate with…
Worked on CEFEPIME HYDROCHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo